Liu Qiang, Yang Gui-Bo, Zhao Hui, Wei Qiang, Xing Hui, Qin Chuan, Shao Yi-Ming
State Key Laboratory for Infectious Diseases Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Biomed Environ Sci. 2008 Aug;21(4):302-7. doi: 10.1016/S0895-3988(08)60046-X.
To develop a model of SHIV-KB9/Chinese origin rhesus (Ch Rh) macaques for vaccine research and to compare the pathogenesis of SHIV-KB9 in Ch Rh macaques with that reported in Indian rhesus (Ind Rh) macaques.
Seven mamu-A*01 negative Ch Rh macaques were inoculated intravenously with 1-10000 MID50 of SHIV-KB9. The monkeys were monitored for viral load, CD4, CD8, SHIV-specific antibody and virus genetic variation. The results were compared with those previously observed in Ind Rh macaques.
As compared to that observed in Ind Rh macaques, SHIV-KB9 in Ch Rh macaques displayed three identical disease progression patterns. However, the primary pattern was not identical between the two subspecies. The level of plasma viremia differed in SHIV-KB9-infected Ch Rh macaques which exhibited different outcomes from those in Ind Rh macaques. Generally, the values of viral load and the maintenance of CD4+ T cells were associated with humoral responses. Otherwise, the viral genetic distances (divergence, diversity) were larger in animals (M419, M425) with their CD4+ T cells profoundly depleted.
The model of SHIV-KB9/Ch Rh macaques displays a relatively slow progression to AIDS compared with Ind Rh macaques, which may more accurately reflect the potential of candidate vaccines in humans.
建立源自中国恒河猴的SHIV-KB9模型用于疫苗研究，并比较SHIV-KB9在中国恒河猴中的发病机制与在印度恒河猴中报道的发病机制。
7只mamu-A*01阴性的中国恒河猴经静脉接种1-10000 MID50的SHIV-KB9。对猴子进行病毒载量、CD4、CD8、SHIV特异性抗体和病毒基因变异的监测。将结果与先前在印度恒河猴中观察到的结果进行比较。
与在印度恒河猴中观察到的情况相比，中国恒河猴中的SHIV-KB9表现出三种相同的疾病进展模式。然而，两个亚种的主要模式并不相同。感染SHIV-KB9的中国恒河猴的血浆病毒血症水平有所不同，其结果与印度恒河猴不同。一般来说，病毒载量值和CD4+T细胞的维持与体液反应相关。否则，在CD4+T细胞严重耗竭的动物（M419、M425）中，病毒基因距离（分歧、多样性）更大。
与印度恒河猴相比，SHIV-KB9/中国恒河猴模型向艾滋病的进展相对较慢，这可能更准确地反映候选疫苗在人类中的潜力。
